Wells Fargo’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $295K | Sell |
95,907
-45,375
| -32% | -$193K | ﹤0.01% | 4462 |
|
|
2025
Q4 | $510K | Buy |
141,282
+48,375
| +52% | +$211K | ﹤0.01% | 4483 |
|
|
2025
Q3 | $350K | Sell |
92,907
-5,471
| -6% | -$21.1K | ﹤0.01% | 4559 |
|
|
2025
Q2 | $381K | Buy |
98,378
+6,697
| +7% | +$36.2K | ﹤0.01% | 4344 |
|
|
2025
Q1 | $458K | Sell |
91,681
-123,857
| -57% | -$785K | ﹤0.01% | 4157 |
|
|
2024
Q4 | $1.55M | Buy |
215,538
+88,209
| +69% | +$674K | ﹤0.01% | 3379 |
|
|
2024
Q3 | $782K | Buy |
127,329
+42,567
| +50% | +$288K | ﹤0.01% | 3698 |
|
|
2024
Q2 | $564K | Buy |
84,762
+25,820
| +44% | +$191K | ﹤0.01% | 3837 |
|
|
2024
Q1 | $600K | Buy |
58,942
+13,731
| +30% | +$140K | ﹤0.01% | 3765 |
|
|
2023
Q4 | $509K | Sell |
45,211
-96,440
| -68% | -$403K | ﹤0.01% | 3856 |
|
|
2023
Q3 | $368K | Buy |
141,651
+105,411
| +291% | +$302K | ﹤0.01% | 3963 |
|
|
2023
Q2 | $128K | Sell |
36,240
-53,497
| -60% | -$240K | ﹤0.01% | 4879 |
|
|
2023
Q1 | $379K | Buy |
89,737
+86,032
| +2,322% | +$1.02M | ﹤0.01% | 4027 |
|
|
2022
Q4 | $60.9K | Sell |
3,705
-1,780
| -32% | -$20K | ﹤0.01% | 4780 |
|
|
2022
Q3 | $70K | Sell |
5,485
-1,075
| -16% | -$15.9K | ﹤0.01% | 4793 |
|
|
2022
Q2 | $76K | Sell |
6,560
-5,262
| -45% | -$32.5K | ﹤0.01% | 4804 |
|
|
2022
Q1 | $72K | Sell |
11,822
-16,058
| -58% | -$118K | ﹤0.01% | 5470 |
|
|
2021
Q4 | $255K | Sell |
27,880
-11,072
| -28% | -$118K | ﹤0.01% | 5125 |
|
|
2021
Q3 | $441K | Sell |
38,952
-140,883
| -78% | -$1.71M | ﹤0.01% | 4729 |
|
|
2021
Q2 | $1.77M | Sell |
179,835
-24,798
| -12% | -$339K | ﹤0.01% | 3792 |
|
|
2021
Q1 | $2.89M | Sell |
204,633
-3,912
| -2% | -$63.2K | ﹤0.01% | 3367 |
|
|
2020
Q4 | $2.35M | Buy |
208,545
+153,447
| +278% | +$1.81M | ﹤0.01% | 3381 |
|
|
2020
Q3 | $727K | Buy |
55,098
+54,810
| +19,031% | +$1.1M | ﹤0.01% | 4090 |
|
|
2020
Q2 | $3K | Buy |
288
+201
| +231% | +$1.1K | ﹤0.01% | 6046 |
|
|
2020
Q1 | $0 | Buy |
+87
| New | +$200 | ﹤0.01% | 6151 |
|
|
2017
Q2 | – | Sell |
-132
| Closed | -$32K | – | 6198 |
|
|
2017
Q1 | $32K | Hold |
132
| – | – | ﹤0.01% | 5586 |
|
|
2016
Q4 | $128K | Buy |
132
+70
| +113% | +$62.7K | ﹤0.01% | 5019 |
|
|
2016
Q3 | $54K | Buy |
+62
| New | +$48.6K | ﹤0.01% | 5260 |
|
|
2013
Q4 | – | Sell |
-3
| Closed | -$2K | – | 5711 |
|
|
2013
Q3 | $2K | Hold |
3
| – | – | ﹤0.01% | 5434 |
|
|
2013
Q2 | $2K | Buy |
+3
| New | +$1.49K | ﹤0.01% | 5363 |
|
Other funds holding ALT
VCM
VPM
N
Wells Fargo's ALT Position: Q1 2026 in Review
Wells Fargo reduced its Altimmune (ALT) stake by 32% in Q1 2026, selling an estimated $193K and leaving 95,907 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #4462.
Wells Fargo first reported a position in ALT in Q2 2013 and has held it in 30 quarters since. The position peaked at $2.89M in Q1 2021. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- Wells Fargo held 95,907 shares of Altimmune worth $295K as of Q1 2026.
- Wells Fargo sold 45,375 Altimmune shares in Q1 2026, an estimated $193K.
- Altimmune made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4462 holding.
- Wells Fargo first reported a position in Altimmune in Q2 2013 and has held it in 30 quarters since.
- Wells Fargo's Altimmune position peaked at $2.89M in Q1 2021.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.